B. Riley Securities lifts Cytosorbents Corporation [CTSO] price estimate. Who else is bullish?

Cytosorbents Corporation [NASDAQ: CTSO] stock went on an upward path that rose over 7.41% on Wednesday, amounting to a one-week price increase of more than 10.93%. The company report on November 2, 2022 that ‘Enhanced Lung Rest’ with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


90-day survival was 74% overall, with early intervention with ECMO and CytoSorb associated with improved survival, and shorter duration on ECMO, mechanical ventilation, and ICU stay compared to late intervention.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using its CytoSorb® blood purification technology, announced the presentation of the final key results from the U.S. multicenter CytoSorb Therapy in COVID-19 (CTC) Registry at the 35th Annual Congress of the European Society of Intensive Care Medicine (ESICM) in Paris last week.  CytoSorb was granted U.S. FDA Emergency Use Authorization (EUA) in April 2020 for use in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure to reduce cytokines and other inflammatory toxins that can cause hyperinflammation.  Severe hyperinflammation is strongly correlated with more severe COVID-19 illness, need for mechanical ventilation, and risk of death.

Over the last 12 months, CTSO stock dropped by -65.48%. The one-year Cytosorbents Corporation stock forecast points to a potential upside of 79.94. The average equity rating for CTSO stock is currently 1.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $85.87 million, with 43.56 million shares outstanding and 39.34 million shares in the current float. Compared to the average trading volume of 137.15K shares, CTSO stock reached a trading volume of 3621392 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Cytosorbents Corporation [CTSO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTSO shares is $10.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTSO stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Cytosorbents Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 17, 2020, representing the official price target for Cytosorbents Corporation stock. Previously, the target price had yet another raise to $15, while SVB Leerink analysts kept a Outperform rating on CTSO stock. On August 08, 2017, analysts increased their price target for CTSO shares from 10 to 12.

The Average True Range (ATR) for Cytosorbents Corporation is set at 0.16, with the Price to Sales ratio for CTSO stock in the period of the last 12 months amounting to 2.28. The Price to Book ratio for the last quarter was 1.86, with the Price to Cash per share for the same quarter was set at 0.71.

CTSO Stock Performance Analysis:

Cytosorbents Corporation [CTSO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.93. With this latest performance, CTSO shares gained by 34.44% in over the last four-week period, additionally sinking by -4.25% over the last 6 months – not to mention a drop of -65.48% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTSO stock in for the last two-week period is set at 64.51, with the RSI for the last a single of trading hit 71.39, and the three-weeks RSI is set at 59.63 for Cytosorbents Corporation [CTSO]. The present Moving Average for the last 50 days of trading for this stock 1.7000, while it was recorded at 1.8400 for the last single week of trading, and 2.4300 for the last 200 days.

Insight into Cytosorbents Corporation Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Cytosorbents Corporation [CTSO] shares currently have an operating margin of -52.69 and a Gross Margin at +74.41. Cytosorbents Corporation’s Net Margin is presently recorded at -56.89.

Return on Equity for this stock declined to -34.64, with Return on Assets sitting at -27.37.

Cytosorbents Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.90.

Cytosorbents Corporation [CTSO] Insider Position Details

There are presently around $32 million, or 39.70% of CTSO stock, in the hands of institutional investors. The top three institutional holders of CTSO stocks are: SKYLANDS CAPITAL, LLC with ownership of 2,347,034, which is approximately 0.948% of the company’s market cap and around 5.80% of the total institutional ownership; AVENIR CORP, holding 2,164,999 shares of the stock with an approximate value of $4.39 million in CTSO stocks shares; and VANGUARD GROUP INC, currently with $3.97 million in CTSO stock with ownership of nearly -10.847% of the company’s market capitalization.

Positions in Cytosorbents Corporation stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 38 institutional holders increased their position in Cytosorbents Corporation [NASDAQ:CTSO] by around 2,053,456 shares. Additionally, 48 investors decreased positions by around 4,552,277 shares, while 16 investors held positions by with 9,132,145 shares. The mentioned changes placed institutional holdings at 15,737,878 shares, according to the latest SEC report filing. CTSO stock had 16 new institutional investments in for a total of 935,776 shares, while 22 institutional investors sold positions of 641,860 shares during the same period.


Please enter your comment!
Please enter your name here